Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Introduction

Some tumors form within the brain and spinal cord, which are both part of the central nervous system (CNS). Treatment for these tumors may include surgery, chemotherapy, and radiation. High dose chemotherapy may damage the person's bone marrow, which is important in making different types of blood cells. In order to restore bone marrow function, a hematopoietic stem cell transplant may be done.

Hematopoietic stem cells are cells that form within the bone marrow and can become many different types of blood cells. In a hematopoietic stem cell transplant, stem cells can be taken from a donor's bone marrow, peripheral blood, or from a newborn baby's umbilical cord blood or placenta shortly after the baby was delivered. The stem cells can also be harvested from the patient himself before he is given any high dose chemotherapy. In all of these cases, the harvested stem cells are then given to the patient, just like in a transfusion. It is hoped that these new stem cells will then settle into the bone marrow and start producing normal blood cells.

If the hematopoietic stem cells are harvested from another person, it is called an allogeneic transplant. If the cells come from the patient himself before his high dose chemotherapy is given, it is called an autologous stem cell transplant. This policy discusses when different types of hematopoietic stem cell transplants might be medically necessary to treat CNS tumors.
**Policy Coverage Criteria**

<table>
<thead>
<tr>
<th>Transplant</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous hematopoietic cell transplantation</td>
<td>Autologous hematopoietic cell transplantation may be considered medically necessary as consolidation therapy for previously untreated embryonal tumors of the central nervous system (CNS) that show partial or complete response to induction chemotherapy, or stable disease after induction therapy (see Additional Information below). Autologous hematopoietic cell transplantation may be considered medically necessary to treat recurrent embryonal tumors of the CNS.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transplant</th>
<th>Investigational</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tandem autologous hematopoietic cell transplantation</td>
<td>Tandem autologous hematopoietic cell transplant is investigational to treat embryonal tumors of the CNS.</td>
</tr>
<tr>
<td>Allogeneic hematopoietic cell transplantation</td>
<td>Allogeneic hematopoietic cell transplantation is investigational to treat embryonal tumors of the CNS.</td>
</tr>
<tr>
<td>Autologous, tandem autologous, and allogeneic hematopoietic cell transplant</td>
<td>Autologous, tandem autologous, and allogeneic hematopoietic cell transplant is investigational to treat ependymoma.</td>
</tr>
</tbody>
</table>

**Additional Information**

In general, use of autologous hematopoietic cell transplantation for previously untreated medulloblastoma has shown no survival benefit for those patients considered to be at average risk (ie, patients older than 3 years of age, without metastatic disease, and with...
Additional Information

total or near total surgical resection [<1.5 cm² residual tumor]) when compared with conventional therapies.

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
</tbody>
</table>

HCPCS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post transplant care in the global definition</td>
</tr>
</tbody>
</table>

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Other CNS tumors include astrocytoma, oligodendroglioma, and glioblastoma multiforme. However, these tumors arise from glial cells and not neuroepithelial cells. These tumors are considered in a separate policy (see Related Policies).

Due to their neuroepithelial origin, peripheral neuroblastoma and Ewing sarcoma may be considered PNETs. However, these peripheral tumors are considered in a separate policy (see Related Policies).
Consideration of Age

The age stated in this policy for which autologous HSCT may be considered medically necessary as consolidation therapy for previously untreated embryonal tumors of the central nervous system that show partial or complete response to induction chemotherapy, or stable disease after induction therapy is age 3 or younger. This is based on scientific evidence that has shown no survival benefit for patients considered to be at average risk (older than 3 years) without metastatic disease and with total or near total surgical resection when compared with conventional therapies. The treatment protocols are based on risk stratification as average or high risk. The average-risk group at 3 years, without metastatic disease, and with tumors that are totally or near totally resected. The high-risk group includes children aged 3 years or younger, or with metastatic disease, and/or subtotal resection.

Benefit Application

The following considerations may supersede this policy:

- State mandates requiring coverage for autologous hematopoietic bone marrow transplantation offered as part of clinical trials of autologous bone marrow transplantation approved by the National Institutes of Health (NIH).

- Some plans may participate in voluntary programs offering coverage for patients participating in NIH-approved clinical trials of cancer chemotherapies, including autologous hematopoietic bone marrow transplantation.

- Some contracts or certificates of coverage may include specific conditions in which autologous hematopoietic bone marrow transplantation would be considered eligible for coverage.

Evidence Review

Description

High-dose chemotherapy (HDC) with hematopoietic cell transplantation (HCT) has been investigated as a possible therapy in pediatric patients with brain tumors, particularly in patients with disease that is considered high risk. In addition, the use of HCT has allowed for a reduction
in the dose of radiation needed to treat both average and high-risk disease, with preservation of quality of life and intellectual functioning, without compromising survival.

Background

Central Nervous System Embryonal Tumors

Classification of brain tumors is based on both histopathologic characteristics of the tumor and location in the brain. Central nervous system (CNS) embryonal tumors are more common in children and are the most common brain tumor in childhood. CNS embryonal tumors are primarily composed of undifferentiated round cells, with divergent patterns of differentiation. It has been proposed that these tumors be merged under the term primitive neuroectodermal tumor (PNET); however, histologically similar tumors in different locations in the brain demonstrate different molecular genetic variants. Embryonal tumors of the CNS include medulloblastoma, medulloepithelioma, supratentorial PNETs (pineoblastoma, cerebral neuroblastoma, ganglioneuroblastoma), ependymoblastoma, atypical teratoid/rhabdoid tumor.

Medulloblastomas account for 20% of all childhood CNS tumors. The other types of embryonal tumors are rare by comparison.

Treatment

Surgical resection is the mainstay of therapy with the goal being gross total resection with adjuvant radiotherapy because medulloblastomas are very radiosensitive. Treatment protocols are based on risk stratification as average or high risk. The average-risk group includes children older than 3 years, without metastatic disease, and with tumors that are totally or near totally resected (<1.5 cm² of residual disease). The high-risk group includes children aged 3 years or younger, or with metastatic disease, and/or subtotal resection (>1.5 cm² of residual disease).

Current standard treatment regimens for average-risk medulloblastoma (postoperative craniospinal irradiation with boost to the posterior fossa followed by 12 months of chemotherapy) have resulted in 5-year overall survival rates of 80% or better. For high-risk medulloblastoma treated with conventional doses of chemotherapy and radiotherapy, the average event-free survival at 5 years ranges from 34% to 40% across studies. Fewer than 55% of children with high-risk disease survive longer than 5 years. The treatment of newly diagnosed medulloblastoma continues to evolve, and in children younger than 3 years of age, because of the concern of the deleterious effects of craniospinal radiation on the immature nervous system,
therapeutic approaches have attempted to delay and sometimes avoid the use of radiation and have included trials of higher dose chemotherapeutic regimens with autologous hematopoietic cell transplantation (HCT).

Supratentorial PNETs are most commonly located in the cerebral cortex and pineal region. The prognosis for these tumors is worse than for medulloblastoma, despite identical therapies. After surgery, children are usually treated similarly to children with high-risk medulloblastoma. Three- to 5-year overall survival rates of 40% to 50% have been reported and, for patients with disseminated disease, survival rates at 5 years range from 10% to 30%.

Recurrent childhood CNS embryonal tumor is not uncommon and, depending on which type of treatment the patient initially received, autologous HCT may be an option. For patients who receive high-dose chemotherapy and autologous HCT for recurrent embryonal tumors, objective response is 50% to 75%; however, long-term disease control is obtained in fewer than 30% of patients and is primarily seen in patients in the first relapse with localized disease at the time of the relapse.

**Ependymoma**

Ependymoma is a neuroepithelial tumor that arises from the ependymal lining cell of the ventricles and is, therefore, usually contiguous with the ventricular system. An ependymoma tumor typically arises intracranially in children, while in adults a spinal cord location is more common. Ependymomas have access to the cerebrospinal fluid and may spread throughout the entire neuroaxis. Ependymomas are distinct from ependymoblastomas due to their more mature histologic differentiation. Initial treatment of ependymoma consists of maximal surgical resection followed by radiotherapy. Chemotherapy usually does not play a role in the initial treatment of ependymoma. However, disease relapse is common, typically occurring at the site of origin.

**Treatment**

Treatment of recurrence is problematic; further surgical resection or radiotherapy is usually not possible. Given the poor response to conventional-dose chemotherapy, high-dose chemotherapy with autologous HCT has been investigated as a possible salvage therapy.

Other CNS tumors include astrocytoma, oligodendroglioma, and glioblastoma multiforme. These tumors arise from glial cells, not neuroepithelial cells.
Due to their neuroepithelial origin, peripheral neuroblastoma and Ewing sarcoma may be considered PNETs.

**Hematopoietic Cell Transplantation**

HCT is a procedure in which hematopoietic cells are infused to restore bone marrow function in cancer patients who receive bone marrow ablative doses of cytotoxic drugs. Bone marrow stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

**HCT for Brain Tumors**

Autologous HCT allows for escalation of chemotherapy doses above those limited by myeloablation and has been tried in patients with high-risk brain tumors in an attempt to eradicate residual tumor cells and improve cure rates. The use of allogeneic HCT for solid tumors does not rely on escalation of chemotherapy intensity and tumor reduction but rather on a graft-versus-tumor effect. Allogeneic HCT is not commonly used in solid tumors and may be used if an autologous source cannot be cleared of tumor or cannot be harvested.

**Summary of Evidence**

For individuals who have newly diagnosed CNS embryonal tumors who receive autologous HCT, the evidence includes prospective and retrospective studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. For pediatric CNS embryonal tumors, an important consideration is whether the use of HCT may allow for a reduction in radiation dose. Data from single-arm studies using HDC with autologous HCT to treat newly diagnosed CNS embryonal tumors have shown comparable or improved survival (both event-free survival and overall survival) compared with historical controls treated with conventional therapy, with or without radiotherapy, particularly in patients with disease considered high risk. In a retrospective comparative study, survival in patients receiving HDC with HCT and delayed craniospinal irradiation was comparable with survival in those receiving upfront craniospinal irradiation. Overall, data from these observational studies have suggested HCT may allow reduced doses of craniospinal irradiation without worsening survival outcomes.
The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have recurrent or relapsed CNS embryonal tumors who receive autologous HCT, the evidence includes prospective and retrospective single-arm studies and a systematic review of these studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. For recurrent/relapsed CNS embryonal tumors, survival outcomes after HCT vary, and survival is generally very poor for tumors other than medulloblastoma. Data from some single-arm studies using autologous HCT to treat recurrent CNS embryonal tumors have shown comparable or improved survival compared with historical controls treated with conventional therapy for certain patients. The results of a 2012 systematic review of observational studies in patients with relapsed supratentorial primitive neuroectodermal tumor suggested that a subgroup of infants with chemosensitive disease might benefit from autologous HCT, achieving survival without the use of radiotherapy, whereas outcomes in older children and/or in pineal location are poor with this modality. However, a relatively large prospective multicenter study has reported that HCT was not associated with improved survival outcomes in patients who had a good response to therapy. Overall, data from these single-arm studies have suggested HCT may be associated with improved survival outcomes in select patients, although data for some tumor types are limited (eg, atypical teratoid/rhabdoid tumors). The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have CNS embryonal tumors who receive tandem autologous HCT, the evidence includes prospective and retrospective single-arm studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. Less evidence specifically addresses the use of tandem autologous HCT for CNS embryonal tumors. The available single-arm studies are very small, but appear to report overall survival and event-free survival rates comparable with single autologous HCT. Tandem transplants might allow reduced doses of craniospinal irradiation, with the goal of avoiding long-term radiation damage. However, most studies used standard-dose irradiation, making the relative benefit of tandem autologous HCT uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have CNS embryonal tumors who receive allogeneic HCT, the evidence includes case reports. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The available evidence is limited. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have ependymoma who receive autologous HCT, the evidence includes relatively small case series. Relevant outcomes are overall survival, disease-specific survival, and
treatment-related mortality and morbidity. The available case series do not report higher survival rates for patients with ependymoma treated with HCT compared with standard therapies. The evidence is insufficient to determine the effects of the technology on health outcomes.

## Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

### Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00653068</td>
<td>Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation</td>
<td>70</td>
<td>Apr 2015 (ongoing)</td>
</tr>
<tr>
<td>NCT00085202</td>
<td>Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor</td>
<td>416</td>
<td>Sep 2018</td>
</tr>
<tr>
<td>NCT02653196</td>
<td>A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors</td>
<td>30</td>
<td>Jul 2019</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01342237</td>
<td>Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors</td>
<td>33</td>
<td>Feb 2014 (unknown)</td>
</tr>
<tr>
<td>NCT00336024</td>
<td>A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children &lt; 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate</td>
<td>96</td>
<td>Dec 2016 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
Practice Guidelines and Position Statements

National Comprehensive Cancer Network Practice Guidelines 2014

Current National Comprehensive Cancer Network guidelines on treating central nervous system (CNS) tumors (v.1.2017) make the following recommendations about hematopoietic cell transplant (HCT)\(^{36}\):

- The guidelines do not address the use of autologous HCT in treating ependymomas.
- For medulloblastoma and supratentorial primitive neuroectodermal tumor, autologous HCT for localized recurrent disease with maximum safe resection is a category 2A recommendation.

American Society for Blood and Marrow Transplantation

In 2015, the American Society for Blood and Marrow Transplantation published consensus guidelines on the use of HCT to treat specific conditions, in both clinical trial and clinical practice settings.\(^{37}\) Per this review, clinical evidence is available to support autologous HCT in pediatric patients (<18 years) with medulloblastoma. Stem cell transplantation is not generally recommended using allogeneic HCT for medulloblastomas. The guidelines did not address HCT in treating ependymomas.

U.S. Preventive Services Task Force Recommendations

Hematopoietic stem-cell transplant is not a preventive service.

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.
Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/01/00</td>
<td>Add to Therapy Section - New Policy — replaces 8.01.15, original master policy on high-dose chemotherapy for miscellaneous malignancies. However, policy statement is unchanged.</td>
</tr>
<tr>
<td>12/11/01</td>
<td>Replace Policy - Policy references updated.</td>
</tr>
<tr>
<td>03/11/03</td>
<td>Replace Policy - Policy updated and references added; no change in policy statement.</td>
</tr>
<tr>
<td>10/12/04</td>
<td>Replace Policy - Policy updated with literature review; policy statement unchanged (text updated for clarification only). Approved by OAP 10/29/04, no need to go back to MPC.</td>
</tr>
<tr>
<td>01/10/06</td>
<td>Replace Policy - Policy updated with literature review; no change to policy statement. Reviewed by OAP 10/27/05.</td>
</tr>
<tr>
<td>06/02/06</td>
<td>Disclaimer and Scope update - No other changes</td>
</tr>
<tr>
<td>11/14/06</td>
<td>Replace Policy - Policy reviewed and recommended by OAP October 26, 2006; no changes to policy statement.</td>
</tr>
<tr>
<td>12/11/07</td>
<td>Replace Policy - Policy updated with literature review. Policy statement added to indicate that multi-cycle high-dose chemotherapy (with or without associated radiotherapy) and autologous stem-cell support (ie, tandem transplants) as investigational. Policy reviewed and recommended by OAP November 15, 2007.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>05/13/08</td>
<td>Cross Reference Update - No other changes</td>
</tr>
<tr>
<td>12/16/08</td>
<td>Replace Policy - Policy updated with literature search; no change to the policy statement. References added. Reviewed and recommended by OAP, August 21, 2008.</td>
</tr>
<tr>
<td>01/13/09</td>
<td>Code Updates - Code added, J8705; effective 1/1/09.</td>
</tr>
<tr>
<td>01/12/10</td>
<td>Replace Policy - Policy extensively revised with literature search; policy title changed to remove “high-dose chemotherapy” and to change PNET to embryonal tumors. Policy statement changed regarding autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy; now considered medically necessary. Other policy statements reworded and separated to address ependymoma and embryonal CNS tumors specifically; however, the intent of the statements remains the same. References added.</td>
</tr>
<tr>
<td>02/09/10</td>
<td>Code Update - New 2010 codes added.</td>
</tr>
<tr>
<td>03/08/11</td>
<td>Replace Policy - Policy updated with literature search through October 2010; references 7, 12-14 added. No change to policy statements.</td>
</tr>
<tr>
<td>05/12/11</td>
<td>Reviewed by OAP - No changes recommended to the policy.</td>
</tr>
<tr>
<td>01/06/12</td>
<td>Replace Policy – Policy updated with literature search. No references added; no change in policy statements. ICD-10 codes added.</td>
</tr>
<tr>
<td>01/24/12</td>
<td>Code 38232 added.</td>
</tr>
<tr>
<td>02/10/12</td>
<td>The CPT code 38204 was removed from the policy.</td>
</tr>
<tr>
<td>06/20/12</td>
<td>Minor update: Related Policies updated; 8.01.17 replaced 8.01.507 effective June 12, 2012.</td>
</tr>
<tr>
<td>07/30/12</td>
<td>Related Policy title updates to: 8.01.17, 8.01.22, 8.01.31, 8.01.35 and 8.01.520. Deleted 8.01.38 as it was archived.</td>
</tr>
<tr>
<td>10/08/12</td>
<td>Update Coding Section – ICD-10 codes are now effective 10/01/2014.</td>
</tr>
<tr>
<td>01/29/13</td>
<td>Replace policy. Policy updated with literature search. References 7, 8, 13 and 18 added; no change in policy statements. Removed CPT codes 38220 and 38221; they do not apply to this policy. Change title to Related Policy 8.01.21.</td>
</tr>
<tr>
<td>03/20/13</td>
<td>The following codes were removed from the policy, as they were not suspending and just informational: HCPCS J9000-J9999 and Q0083 – Q0085.</td>
</tr>
<tr>
<td>09/30/13</td>
<td>Update Related Policies. Change policy title to 8.01.31.</td>
</tr>
<tr>
<td>10/18/13</td>
<td>Update Related Policies. Change title to policy 8.01.17.</td>
</tr>
<tr>
<td>01/21/14</td>
<td>Replace policy. Policy updated with literature search through October 8, 2013. References 13 and 14 added, references 3 and 24 updated; no change in policy statements. Remove CPT code 38230; it does not apply to this policy.</td>
</tr>
<tr>
<td>03/21/14</td>
<td>Update Related Policies. Remove 801.514 as it was deleted.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>04/18/14</td>
<td>Update Related Policies. Remove 8.01.20 and replace with 8.01.529.</td>
</tr>
<tr>
<td>06/24/14</td>
<td>Update Related Policies. Remove 8.01.35, 8.01.42 and 8.01.54, then add 8.01.530, 8.01.531 and 8.01.532.</td>
</tr>
<tr>
<td>12/03/14</td>
<td>Update Related Policies. Remove 8.01.17 and 8.01.26.</td>
</tr>
<tr>
<td>01/28/15</td>
<td>Annual Review. Policy updated with literature review through September 30, 2014. References 5-6, 9, 15, and 17-19 added. Policy statements unchanged. ICD-9 and ICD-10 diagnosis codes removed; these are not utilized in policy adjudication.</td>
</tr>
<tr>
<td>05/01/16</td>
<td>Annual Review, approved April 12, 2016. Policy updated with literature review through October 27, 2015; references 4-6 and 9 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>11/04/16</td>
<td>Coding update. Removed codes that are transplant benefit related.</td>
</tr>
<tr>
<td>04/01/17</td>
<td>Annual Review, approved March 14, 2017. Policy updated with literature review through November 7, 2016; references 6, and 22-23 added. Changed “hematopoietic stem cell transplantation” to “hematopoietic cell transplantation” per NCCN terminology change. Policy statements unchanged.</td>
</tr>
<tr>
<td>11/10/17</td>
<td>Policy moved to new format, no changes to policy statement.</td>
</tr>
<tr>
<td>09/01/18</td>
<td>Minor update. Re-added Consideration of Age information, which was inadvertently removed during a previous update.</td>
</tr>
</tbody>
</table>

**Disclaimer**: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope**: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
**Getting Help in Other Languages**

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action because of race, color, national origin, age, disability, or sex.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

**Civil Rights Coordinator - Complaints and Appeals**
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

If you need these services, contact the Civil Rights Coordinator.

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at [https://ocrportal.hhs.gov/ocr/portal/lobby.jsf](https://ocrportal.hhs.gov/ocr/portal/lobby.jsf), or by mail or phone at:

**U.S. Department of Health and Human Services**
200 Independence Avenue SW, Room 509F, HHH Building Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)


**Get Help by Phone**

- **Premera Blue Cross**
  - English, such as:
    - Qualified interpreters
    - Written information in other formats (large print, audio, accessible electronic formats, other formats)
  - Qualified sign language interpreters
  - Written information in other languages (large print, audio, accessible electronic formats, other formats)
  - Language assistance services

**Oromo (Cushite):**


**Italiano (Italian):**

Premera Blue Cross.


Tagalog (Tagalog):

ไทย (Thai):
ประกาศนี้มีข้อมูลที่น่าสนใจเกี่ยวกับการขอประกันสุขภาพของคุณผ่าน Premera Blue Cross. โปรดติดต่อเราที่ 800-722-1471 (TTY: 800-842-5357) ถ้าคุณมีปัญหา.

Tiếng Việt (Vietnamese):

Română (Romanian):

Russkiy (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Español (Spanish):
Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

Polski (Polish):

Português (Portuguese):
Este aviso contém importantes informações. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde e ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357).

한국어 (Korean):
본 통지서에는 중요한 정보가 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross를 통해 커버리지에 관한 정보를 포함하고 있습니다. 본 통지서에는 흔히 없는 날짜들이 있을 수 있습니다. 귀하의 커버리지를 제외하거나 다른 것을 절대히 있어서 일정한 마감일까지 조치할 필요가 있을 수 있습니다. 귀하의 경우와 동일하게 귀하의 언어와 비용 부담없이 될 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357)로 전화하십시오.

لغة فارسية (Persian):
این اطلاعیه جویای طرح‌های مبادیت این است که یک کاربر دیگر اطلاعات مهم بیمار در نظر گرفته است. این اطلاعیه باید شما را از طریق یک همکار به تغییر دهنده هسته‌های مدیریتی نشان دهد. همکاری به راه‌پیمایی به شماره‌ای که در پنجرهی این مورد نگه‌داری می‌شود، ممکن است برای یک کارکردی در سطح وفاداری هدایت شود. این را برای کسب اطلاعات و کمک را به راه‌پیمایی به حرکت برجسته در تلاشهای مدیریت اطلاعات در شماره 800-722-1471 (کارکرد 800-842-5357) با رصد نمایید.

Français (French):
Annexe à un accord de couverture d'un service de santé. Cette annexe contient des informations importantes concernant votre entrée dans le service de santé. Assurez-vous de lire attentivement cette annexe avant de prendre des décisions importantes. Appelez 800-722-1471 (TTY: 800-842-5357) pour obtenir plus d'informations.

日本語 (Japanese):
この通知には重要な情報が含まれています。この通知には、Premera Blue Crossの申請または補償範囲に関する重要な情報が含まれている場合があります。この通知には記載されている可能性がある重要な日付をご確認ください。医療保険や保険サービスを維持する上には、特定の期限までに行動を取りなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

한국어 (Korean):
본 통지서에는 중요한 정보가 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross를 통해 커버리지에 관한 정보를 포함하고 있습니다. 본 통지서에는 흔히 없는 날짜들이 있을 수 있습니다. 귀하의 커버리지를 제외하거나 다른 것으로 절대적 급여가 있을 수 있습니다. 귀하의 경우와 동일하게 귀하의 언어와 비용 부담없이 될 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357)로 전화하십시오.